Joey's Fight For Sight Inc

June 2009
Hudson Valley Business Journal;6/15/2009, Vol. 19 Issue 23, p5
The article offers information on Joey's Fight for Sight Inc.'s first roller skating benefit which will be held at Wood N Wheel in Port Ewen, New York on June 27, 2009. It states that the proceeds from the event will cover for the stem cell treatment of blind Joseph Simmons who was diagnosed with Septo-Optic Dysplasia (SOD) at infancy. It adds that Fight for Sight Inc. will hold numerous fund raising events to finance the costly stem cell treatment that is not covered by medical insurance.


Related Articles

  • Stem-Cell Therapy for Pets. Lee-St. John, Jeninne // Time International (South Pacific Edition);8/11/2008, Issue 31, p46 

    The article describes veterinary stem-cell therapy. The therapy, promoted by Vet-Stem Inc., transplants fat-derived stem cells. Conditions treated by the therapy are described, including arthritis, hip dysplasia, and tendon injuries. The article also mentions that most animals show improvement...

  • Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. De Padua Silva, L.; de Lima, M.; Kantarjian, H.; Faderl, S.; Kebriaei, P; Giralt, S.; Davisson, J.; Garcia-Manero, G.; Champlin, R.; Issa, J.-P; Ravandi, F. // Bone Marrow Transplantation;Jun2009, Vol. 43 Issue 11, p839 

    Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is largely unknown whether treatment with this drug before allo-SCT will increase the toxicity of the preparative regimen or otherwise affect the results of the transplant. We report the outcome of 17...

  • Breakthrough in Stem Cell Therapy.  // India -- West;7/16/2010, Vol. 25 Issue 34, pA41 

    The article reports on the success of an autologous stem cell-based therapy procedure in a nine-month-old dog conducted by researchers at Tamil Nadu Veterinary and Animal Sciences in India.

  • Carboplatin/etoposide: Intrapulmonary haemorrhage: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p96 

    A 71-year-old woman developed pruritus and acneiform skin rash during treatment with erlotinib for lung adenocarcinoma. Additionally, the acneiform skin rash and pruritus worsened following concomitant administration of erlotinib and aprepitant for lung adenocarcinoma.

  • Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Tauro, S; Shankaranarayana, P; Nitu-Whalley, I C; Duncan, N; Begum, G; Craig, J I O; Marcus, R E; Craddock, C F; Mahendra, P // Bone Marrow Transplantation;Aug2003, Vol. 32 Issue 3, p273 

    Summary:Stem cell transplantation (SCT) may be the only curative option for patients with relapsed or refractory leukaemia, that is, high-risk (HR) leukaemia. Several salvage regimens have been used to cytoreduce disease before SCT, but disease progression or treatment toxicity limits numbers of...

  • Impact of new Therapies on Nursing Care.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS255 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S255–S256. DOI: 10.1038/sj/bmt/1703498

  • RESEARCH HIGHLIGHTS. Carroll, Suzanne; Hodges, Lisa; King, Cynthia R. // Oncology Nursing Forum;Jul2006, Vol. 33 Issue 4, p693 

    Summarizes research related to oncology. "Once Weekly Oral Alendronate Prevents Bone Loss in Men in Androgen Deprivation Therapy," by J. B. Nelson, S. L. Greenspan et al.; "Thalidomide and Hematopoietic Stem-cell Transplantation for Multiple Myeloma," by B. Barlogie, G. Tricot et al.; "The...

  • Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Bartlett, Marissa L.; Webb, Myles; Durrant, Simon; Morton, James A.; Allison, Roger; Macfarlane, David J. // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 11, p1470 

    Standard treatment regimens for haematological malignancies include myeloablative chemoradiotherapy and subsequent rescue by stem cell transplantation. However, these treatment regimens have significant associated mortality and morbidity, and disease recurrence remains a problem. One alternative...

  • Antithymocyte globulin/cyclophosphamide/etoposide.  // Reactions Weekly;12/18/2010, Issue 1332, p11 

    The article describes the case of a 19-year-old man who presented with acute disseminated fatal toxoplasmosis following stem cell transplantation (SCT) with cyclophosphamide, antithymocyte globulin and etoposide for preconditioning, referencing a study published in the November 2010 issue of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics